Velagliflozin (Senvelgo) for Feline Diabetes Mellitus: SGLT2 Inhibition, Efficacy and Safety

Bottom line.

• The SENSATION study, a prospective baseline-controlled open-label field trial in 252 client-owned diabetic cats receiving velagliflozin oral solution once daily, showed median blood glucose decreased from a screening value of 436 mg/dL to 153 mg/dL at day 30, 134 mg/dL at day 60, 128 mg/dL at day 120, and 125 mg/dL at day 180; 85% of enrolled cats were naïve (insulin-untreated) diabetics.¹
• Peripheral neuropathy improved in >75% of affected cats treated with velagliflozin; 38–50% of cats experienced changes in stool consistency within the first 2 weeks, typically mild and self-limiting.¹
• Reported incidence of euglycemic diabetic ketoacidosis (EDKA) in velagliflozin-treated cats is 5–7%, the same as the incidence of DKA in insulin-treated cats; EDKA is most common in the first 2 weeks and affected cats are often hyporexic and lethargic with blood BHB typically >2.4 mmol/L.^1,2
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor.¹
• Mechanism: Blocks reabsorption of glucose in the renal proximal convoluted tubules, promoting urinary glucose excretion and lowering blood glucose independent of endogenous insulin.²
• Formulation/route: Oral solution (15 mg/mL); administered once daily directly into the mouth or with a small amount of food.¹
• FDA approval: August 2023 (Senvelgo, Boehringer Ingelheim); indicated to improve glycemic control in cats with diabetes mellitus not previously treated with insulin.³
• Key trial population: Client-owned diabetic cats; 214/252 (85%) naïve (not previously treated with insulin) and 38/252 (15%) previously insulin-treated.¹

Managing a diabetic cat?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific evidence, monitoring plans, and dosing guidance to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

The SENSATION study — design and population

The SENSATION study (Behrend et al. 2024, JAVMA) was a prospective, baseline-controlled, open-label clinical field trial evaluating the safety and effectiveness of velagliflozin oral solution as sole therapy in 252 client-owned cats.¹ Of these, 214 (85%) were naïve diabetics not previously treated with insulin and 38 (15%) were insulin-treated diabetics. Cats received velagliflozin orally once daily; physical examinations and blood collections were performed on days 0, 3, 7, 30, 60, 120, and 180. The screening blood glucose was 436 mg/dL (interquartile range 272 to 676 mg/dL).

Blood glucose outcomes

Velagliflozin produced rapid and sustained reductions in blood glucose. Median blood glucose values after administering velagliflozin were:¹

• Day 30: 153 mg/dL (range 62–480 mg/dL)
• Day 60: 134 mg/dL (range 64–414 mg/dL)
• Day 120: 128 mg/dL (range 55–461 mg/dL)
• Day 180: 125 mg/dL (range 77–384 mg/dL)

Serum fructosamine concentrations were routinely within the reference range after 8 weeks of treatment.² Clinical signs of diabetes mellitus (polyuria, polydipsia, polyphagia) improved in the majority of cats despite persistent glucosuria.

Peripheral neuropathy

One of the distinctive findings of the SENSATION study was the effect on diabetic peripheral neuropathy. Peripheral neuropathy — characterized by a plantigrade stance limiting cats' ability to run and jump — improved in more than 75% of affected cats treated with velagliflozin.¹ This is consistent with the glucose-toxicity reversal mechanism of SGLT2 inhibition.

Adverse events — gastrointestinal

Approximately 38–50% of cats had changes in stool consistency within the first 2 weeks of SGLT2 inhibitor administration.^1,2 This is attributed to mild cross-inhibition of sodium-glucose transporter 1 in the small intestine, resulting in osmotic diarrhea. The effect is typically modest and self-limiting; antibiotic therapy is not indicated. Vomiting was also commonly reported but tended to be sporadic. If the cat is eating well and stable, velagliflozin can be safely redosed if the cat vomits within 30 minutes of dosing.

DKA and euglycemic DKA risk

The most serious complication with velagliflozin is DKA, most commonly euglycemic DKA (EDKA), in which acid-base and electrolyte derangements occur despite blood glucose <250 mg/dL.¹ The reported incidence of EDKA in cats treated with an SGLT2 inhibitor is 5–7%, the same as the incidence of DKA in cats treated with insulin. EDKA is most common during the first 2 weeks of therapy. Cats previously treated with insulin appear predisposed. Affected cats are often hyporexic and lethargic, and blood BHB is typically >2.4 mmol/L. Monitoring blood BHB is essential during the early treatment period; the 2026 AAHA Diabetes Management Guidelines for Cats describe a recommended monitoring schedule with BHB checks at days 2–3, 7, 14, and 30.²

Velagliflozin vs insulin — head-to-head evidence

A comparative randomized trial by Niessen et al. (2024, JVIM) evaluated efficacy and safety of once-daily oral velagliflozin versus twice-daily insulin injections in diabetic cats.⁴ Results supported non-inferiority of velagliflozin for glycemic control, with additional benefits of oral administration obviating the need for twice-daily injections, reducing compliance barriers for many owners.

SGLT2 inhibitor contraindications

Per the 2026 AAHA guidelines and the velagliflozin package insert, velagliflozin should not be started if ketonuria is detected, and detecting ketonuria during treatment should prompt discontinuation and transition to insulin.² Velagliflozin is approved only for newly diagnosed cats not previously treated with insulin; cats with systemic compromise (vomiting, hyporexia, cachexia, lethargy) or conditions such as significant CKD (IRIS Stage 3+), hypercalcemia, or hepatopathy should receive insulin therapy instead.²

How this fits clinical practice

Velagliflozin occupies a new therapeutic niche in feline diabetes: an oral once-daily liquid that lowers blood glucose via an insulin-independent mechanism, reduces glucose toxicity, and can facilitate diabetic remission by allowing beta-cell recovery. The 2026 AAHA Diabetes Management Guidelines for Cats identify SGLT2 inhibitors alongside insulin as the two licensed treatment modalities for feline DM, with SGLT2 inhibitors an appropriate treatment option for a substantial proportion of newly diagnosed, metabolically stable patients.² The requirement for BHB monitoring — particularly in the first 2 weeks — is a critical component of safe use. Do not infer specific doses or monitoring cut-offs from this article; consult current product labeling and AAHA 2026 guidelines.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Behrend EN, Ward CR, Chukwu V, Cook AK, Kroh C, Lathan P, May J, Schermerhorn T, Scott-Moncrieff JC, Voth R. 2024. Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study. J Am Vet Med Assoc 262(10):1343–53. https://avmajournals.avma.org/view/journals/javma/262/10/javma.24.03.0174.xml
2. American Animal Hospital Association. 2026. 2026 AAHA Diabetes Management Guidelines for Cats — Section 6: SGLT2 Inhibitor Treatment and Monitoring. https://www.aaha.org/resources/2026-aaha-diabetes-management-guidelines-for-cats/section-6-sglt2-inhibitor-treatment-and-monitoring/
3. Boehringer Ingelheim Animal Health. 2023. Boehringer Ingelheim receives FDA approval for SENVELGO (velagliflozin oral solution): the first oral liquid medication for diabetes in cats. https://animalhealth.boehringer-ingelheim.com/articles/senvelgo-cat-diabetes-fda-approval-boehringer-ingelheim-oral-liquid-medication
4. Niessen SJ, Kooistra HS, Forcada Y, et al. 2024. Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats. J Vet Intern Med 38(4):2099–119.

Changelog

• 2026-06-26: First published.